Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of BI 655064 in Healthy Chinese Male Volunteers (Randomised, Double-blind, Placebo-controlled, Clinical Phase I Study)
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs BI 655064 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 31 May 2016 Status changed from active, no longer recruiting to completed.
- 06 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 06 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.